Takeda Pharmaceutical Co ( (JP:4502) ) just unveiled an update.
Takeda Pharmaceutical Co. has completed the acquisition of 11,823,500 of its own shares, amounting to a cost of JPY 49,977,956,800, as part of a resolution made by its Board of Directors. This move, executed through an open-market repurchase via a trust bank, is part of a broader strategy to acquire up to 28.5 million shares, reflecting Takeda’s efforts to optimize its capital structure and potentially increase shareholder value.
More about Takeda Pharmaceutical Co
Takeda Pharmaceutical Company Limited is a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan. The company focuses on creating better health for people and a brighter future for the world by discovering and delivering life-transforming treatments in core therapeutic areas such as gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience, and vaccines. Takeda operates in approximately 80 countries and regions, driven by a commitment to patients, people, and the planet.
YTD Price Performance: 11.64%
Average Trading Volume: 45,835
Technical Sentiment Signal: Strong Sell
Current Market Cap: $48.19B
Learn more about 4502 stock on TipRanks’ Stock Analysis page.